Related Experiment Videos
Biological activity of Hib conjugates
P P Vella1, J M Staub, R W Ellis
1Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Vaccine
|June 1, 1991
Summary
New Hib conjugate vaccines show promise. PedvaxHIB is immunogenic in infant rhesus monkeys, correlating with human studies, unlike HibTITER which requires further study regarding diphtheria toxoid's role.
Area of Science:
- Pediatric Vaccinology
- Immunology
- Microbiology
Background:
- Haemophilus influenzae type b (Hib) conjugate vaccines enhance immunogenicity against Hib's capsular polysaccharide (PRP).
- Evaluating new Hib conjugate vaccines in preclinical models is crucial for predicting human efficacy.
- The infant rhesus monkey model is a relevant correlate for assessing Hib conjugate vaccine immunogenicity in humans.
Purpose of the Study:
- To assess the immunogenicity of a new Hib conjugate vaccine, PedvaxHIB, in infant rhesus monkeys.
- To evaluate the infant rhesus monkey model's correlation with human clinical studies of PedvaxHIB.
- To compare the immunogenicity of PedvaxHIB and HibTITER in an immune-naive primate model.
Main Methods:
- Infant rhesus monkeys were immunized with PedvaxHIB.
- Immunogenicity was assessed in the infant rhesus monkey model.
- Comparison of immunogenicity between PedvaxHIB and HibTITER was performed.
Main Results:
- PedvaxHIB demonstrated immunogenicity in infant rhesus monkeys.
- The monkey model showed good correlation with human clinical data for PedvaxHIB.
- HibTITER was not immunogenic in immune-naive infant rhesus monkeys, suggesting a role for prior diphtheria toxoid exposure.
Conclusions:
- PedvaxHIB is a potentially effective Hib conjugate vaccine, supported by preclinical primate data.
- The infant rhesus monkey model serves as a valuable predictive tool for Hib conjugate vaccine immunogenicity.
- Further investigation into the role of diphtheria toxoid in HibTITER's immunogenicity in human infants is warranted.